Segment Reporting

12 Months Ended

Jun. 30, 2026

Disclosure of operating segments [abstract]

Note 15. Segment Reporting

Description of segments and principal activities

The group has identified its operating segments based on the internal reports that are reviewed and used by the executive management team in assessing performance and determining the allocation of resources. The executive management uses the measure of profit and loss to assess segment performance.

Management considers the business from both a product and a geographic perspective and has identified two reportable segments:

Research and development (R&D): income and expenses directly attributable to the group’s R&D projects performed in Australia and United States.

Hyper-immune products: income and expenses directly attributable to Travelan and Protectyn activities which occur in Australia, the United States, Canada and the rest of the world.

Financial breakdown

The segment information for the reportable segments for the year ended June 30, 2026 is as follows:

	Research and development			Hyper-immune products			Corporate			Total
2026	A$			A$			A$			A$
Hyper-immune products revenue		-			7,713,601			-			7,713,601
Cost of sales of goods		-			(2,738,529	)		-			(2,738,529	)
Gross profit		-			4,975,072			-			4,975,072
Other income		1,122,132			47,737			-			1,169,869
Net foreign exchange gains/(losses)		-			-			(285,115	)		(285,115	)
Movement in inventory provision		-			-			-			-
General and administrative expenses		-			-			(4,305,555	)		(4,305,555	)
Research and development expenses		(1,933,440	)		-			-			(1,933,440	)
Selling and marketing expenses		-			(3,471,556	)		-			(3,471,556	)
Operating profit/(loss)		(811,308	)		1,551,253			(4,590,670	)		(3,850,725	)
Finance income		-			-			185,438			185,438
Finance costs		-			-			(14,712	)		(14,712	)
Share of loss from associates		-			-			-			-
Profit/(loss) for the year		(811,308	)		1,551,253			(4,419,944	)		(3,679,999	)
Assets
Segment assets		782,313			2,900,653			9,468,732			13,151,698
Total assets		782,313			2,900,653			9,468,732			13,151,698
Liabilities
Segment liabilities		179,995			744,280			1,062,396			1,986,671
Total liabilities		179,995			744,280			1,062,396			1,986,671

The segment information for the reportable segments for the year ended June 30, 2025 is as follows:

	Research and development			Hyper-immune products			Corporate			Total
2025	A$			A$			A$			A$
Hyper-immune products revenue		-			7,287,002			-			7,287,002
Cost of sales of goods		-			(2,521,903	)		-			(2,521,903	)
Gross profit		-			4,765,099			-			4,765,099
Other income		1,380,993			30,512			-			1,411,505
Net foreign exchange gains/(losses)		-			-			12,183			12,183
General and administrative expenses		(562,960	)		-			(3,920,663	)		(4,483,623	)
Research and development expenses		(3,597,296	)		-			-			(3,597,296	)
Selling and marketing expenses		-			(3,452,416	)		-			(3,452,416	)
Operating profit/(loss)		(2,779,263	)		1,343,195			(3,908,480	)		(5,344,548	)
Finance income		-			-			135,866			135,866
Finance costs		-			-			(7,305	)		(7,305	)
Profit/(loss) for the year		(2,779,263	)		1,343,195			(3,779,919	)		(5,215,987	)

Assets
Segment assets		1,110,514			1,737,563			7,281,765			10,129,842
Total assets		1,110,514			1,737,563			7,281,765			10,129,842

Liabilities
Segment liabilities		230,875			617,461			1,212,451			2,060,787
Total liabilities		230,875			617,461			1,212,451			2,060,787

The segment information for the reportable segments for the year ended June 30, 2024 is as follows:

	Research and development			Hyper-immune products			Corporate			Total
2024	A$			A$			A$			A$
Hyper-immune products revenue		-			4,902,865			-			4,902,865
Cost of sales of goods		-			(1,566,068	)		-			(1,566,068	)
Gross profit		-			3,336,797			-			3,336,797
Other income		3,364,439			43,760			-			3,408,199
Fair value losses to financial assets		-			-			(557,676	)		(557,676	)
Net foreign exchange gains/(losses)		-			-			(27,603	)		(27,603	)
General and administrative expenses		(460,251	)		(3,565	)		(4,091,910	)		(4,555,726	)
Research and development expenses		(5,375,461	)		-			-			(5,375,461	)
Selling and marketing expenses		-			(2,029,648	)		-			(2,029,648	)
Operating profit/(loss)		(2,471,273	)		1,347,344			(4,677,189	)		(5,801,118	)
Finance income		-			-			327,756			327,756
Finance costs		-			-			(7,576	)		(7,576	)
Share of loss from associates		-			-			(1,456,019	)		(1,456,019	)
Profit/(loss) for the year		(2,471,273	)		1,347,344			(5,813,028	)		(6,936,957	)
Assets
Segment assets		768,370			2,845,096			11,936,503			15,549,969
Total assets		768,370			2,845,096			11,936,503			15,549,969
Liabilities
Segment liabilities		604,018			206,524			2,029,983			2,840,525
Total liabilities		604,018			206,524			2,029,983			2,840,525

Information on geographical regions:

The group derives revenue from the transfer of hyper-immune products at a point in time in the following major product lines and geographical regions:

	Travelan						ProIBS		Protectyn
	Australia		United States		Canada		Australia		Australia		Total
2026	A$		A$		A$		A$		A$		A$
Hyper-immune products revenue		5,672,502		1,768,411		165,668		85,221		21,799		7,713,601
Revenue from external customers		5,672,502		1,768,411		165,668		85,221		21,799		7,713,601

	Travelan						Protectyn
	Australia		United States		Canada		Australia		Total
2025	A$		A$		A$		A$		A$
Hyper-immune products revenue		5,201,385		1,658,336		378,706		48,575		7,287,002
Revenue from external customers		5,201,385		1,658,336		378,706		48,575		7,287,002

	Travelan						Protectyn
	Australia		United States		Canada		Australia		Total
2024	A$		A$		A$		A$		A$
Hyper-immune products revenue		3,702,876		1,075,614		80,888		43,487		4,902,865
Revenue from external customers		3,702,876		1,075,614		80,888		43,487		4,902,865

Information on major customers:

During the years ended June 30, 2026, 2025 and 2024, the Company had the following major customers in the hyper-immune product segment with revenues amounting to 10 percent or more of total group revenues:

	2026 A$		2025 A$		2024 A$
Customer A		4,199,953		3,272,556		2,308,425
Customer B		1,239,030		1,558,156		957,076
Customer C		1,045,802		958,031		842,173
Customer D		977,392		860,086		552,509
		7,462,177		6,648,829		4,660,183